MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines

World Journal of Gastroenterology

Volumn 20, Issue 40, 2014, Pages 14904-14912

  Hummel, Richard ^a,b   Sie, Corina ^a   Watson, David I ^a   Wang, Tingting ^a   Ansar, Alfiya ^a   Michael, Michael Z ^a   Van Der Hoek, Mark ^c   Haier, Joerg ^b   Hussey, Damian J ^a  

^a FLINDERS UNIVERSITY   (Australia)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c Adelaide Microarray Centre   (Australia)

Author keywords

Chemotherapy; Esophageal cancer; MicroRNA; Resistance; Target

Indexed keywords

CISPLATIN; FLUOROURACIL; MESSENGER RNA; MICRORNA; MICRORNA 125A 5P; MICRORNA 18A 3P; MICRORNA 192 5P; MICRORNA 193B 3P; MICRORNA 27B 3P; MICRORNA 378 A 3P; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; ESOPHAGEAL CANCER CELL LINE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; ADENOCARCINOMA; CELL SURVIVAL; COMPARATIVE STUDY; DNA MICROARRAY; DRUG EFFECTS; DRUG RESISTANCE; ESOPHAGUS TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; FLUOROURACIL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84910593157     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i40.14904     Document Type: Article

References (28)

1. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8: 226-234 [PMID: 17329193 DOI: 10.1016/s1470-2045(07)70039-6]
2. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12: 681-692 [PMID: 21684205 DOI: 10.1016/ S1470-2045(11)70142-5]
3. Pike GK, Bessell JR, Mathew G, Watson DI, Mitchell PC, Jamieson GG. Changes in fibrinogen levels in patients undergoing open and laparoscopic Nissen fundoplication. Aust N Z J Surg 1996; 66: 94-96 [PMID: 8602823 DOI: 10.1111/ j.1445-2197.1996.tb01120.x]
4. Mayne GC, Hussey DJ, Watson DI. MicroRNAs and esophageal cancer - implications for pathogenesis and therapy. Curr Pharm Des 2013; 19: 1211-1226 [PMID: 23092342 DOI: 10.2174 /1381612811319070005]
5. Hiyoshi Y, Kamohara H, Karashima R, Sato N, Imamura Y, Nagai Y, Yoshida N, Toyama E, Hayashi N, Watanabe M, Baba H. MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res 2009; 15: 1915-1922 [PMID: 19276261 DOI: 10.1158/1078-0432. CCR-08-2545]
6. Hummel R, Hussey DJ, Haier J. MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 2010; 46: 298-311 [PMID: 19948396 DOI: 10.1016/j.ejca.2009.10.027]
7. Hummel R, Watson DI, Smith C, Kist J, Michael MZ, Haier J, Hussey DJ. Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. J Gastrointest Surg 2011; 15: 429-438 [PMID: 21246413 DOI: 10.1007/s11605-011-1418-9]
8. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. JRSS Series B 1995; 57: 289-300
9. Papadopoulos GL, Alexiou P, Maragkakis M, Reczko M, Hatzigeorgiou AG. DIANA-mirPath: Integrating human and mouse microRNAs in pathways. Bioinformatics 2009; 25: 1991-1993 [PMID: 19435746 DOI: 10.1093/bioinformatics/ btp299]
10. Krasnapolski MA, Todaro LB, de Kier Joffé EB. Is the epithelial-to-mesenchymal transition clinically relevant for the cancer patient? Curr Pharm Biotechnol 2011; 12: 1891-1899 [PMID: 21470129 DOI: 10.2174/138920111798377021]
11. Davids MS, Letai A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol 2012; 30: 3127-3135 [PMID: 22649144 DOI: 10.1200/JCO.2011.37.0981]
12. Sabine VS, Sims AH, Macaskill EJ, Renshaw L, Thomas JS, Dixon JM, Bartlett JM. Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer. Breast Cancer Res Treat 2010; 122: 419-428 [PMID: 20480226 DOI: 10.1007/s10549-010-0928-6]
13. de Bruijn MT, Raats DA, Hoogwater FJ, van Houdt WJ, Cameron K, Medema JP, Borel Rinkes IH, Kranenburg O. Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa. Br J Cancer 2010; 102: 1254-1264 [PMID: 20354524 DOI: 10.1038/ sj.bjc.6605633]
14. López-Guerra M, Trigueros-Motos L, Molina-Arcas M, Villamor N, Casado FJ, Montserrat E, Campo E, Colomer D, Pastor-Anglada M. Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells. Haematologica 2008; 93: 1843-1851 [PMID: 18945750 DOI: 10.3324/haematol. 13186]
15. St Croix B, Kerbel RS. Cell adhesion and drug resistance in cancer. Curr Opin Oncol 1997; 9: 549-556 [PMID: 9370076 DOI: 10.1097/00001622-199711000-00010]
16. Marsh S. Thymidylate synthase pharmacogenetics. Invest New Drugs 2005; 23: 533-537 [PMID: 16267625 DOI: 10.1007/ s10637-005-4021-7]
17. Zhou SF, Wang LL, Di YM, Xue CC, Duan W, Li CG, Li Y. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem 2008; 15: 1981-2039 [PMID: 18691054 DOI: 10.2174/092986708785132870]
18. Zhang Y, Qu X, Hu X, Yang X, Hou K, Teng Y, Zhang J, Sada K, Liu Y. Reversal of P-glycoprotein-mediated multi-drug resistance by the E3 ubiquitin ligase Cbl-b in human gastric adenocarcinoma cells. J Pathol 2009; 218: 248-255 [PMID: 19274672 DOI: 10.1002/path.2533]
19. Chen X, Yeung TK, Wang Z. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3. Biochem Biophys Res Commun 2000; 277: 757-763 [PMID: 11062025 DOI: 10.1006/bbrc.2000.3731]
20. Ren J, Agata N, Chen D, Li Y, Yu WH, Huang L, Raina D, Chen W, Kharbanda S, Kufe D. Human MUC1 carcinomaassociated protein confers resistance to genotoxic anticancer agents. Cancer Cell 2004; 5: 163-175 [PMID: 14998492 DOI: 10.1016/s1535-6108(04)00020-0]
21. Nishida N, Mimori K, Fabbri M, Yokobori T, Sudo T, Tanaka F, Shibata K, Ishii H, Doki Y, Mori M. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res 2011; 17: 2725-2733 [PMID: 21220473 DOI: 10.1158/1078-0432.CCR-10-2132]
22. Boni V, Bitarte N, Cristobal I, Zarate R, Rodriguez J, Maiello E, Garcia-Foncillas J, Bandres E. miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation. Mol Cancer Ther 2010; 9: 2265-2275 [PMID: 20647341 DOI: 10.1158/1535-7163.MCT-10-0061]
23. Fang Y, Fang D, Hu J. MicroRNA and its roles in esophageal cancer. Med Sci Monit 2012; 18: RA22-RA30 [PMID: 22367141 DOI: 10.12659/msm.882509]
24. Imanaka Y, Tsuchiya S, Sato F, Shimada Y, Shimizu K, Tsujimoto G. MicroRNA-141 confers resistance to cisplatin-induced apoptosis by targeting YAP1 in human esophageal squamous cell carcinoma. J Hum Genet 2011; 56: 270-276 [PMID: 21289630 DOI: 10.1038/jhg.2011]
25. Zhang H, Li M, Han Y, Hong L, Gong T, Sun L, Zheng X. Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci 2010; 55: 2545-2551 [PMID: 19960259 DOI: 10.1007/s10620-009-1051-6]
26. Lynam-Lennon N, Reynolds JV, Marignol L, Sheils OM, Pidgeon GP, Maher SG. MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma. J Mol Med (Berl) 2012; 90: 1449-1458 [PMID: 22706599 DOI: 10.1007/s00109-012-0924-x]
27. Hamano R, Miyata H, Yamasaki M, Kurokawa Y, Hara J, Moon JH, Nakajima K, Takiguchi S, Fujiwara Y, Mori M, Doki Y. Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin Cancer Res 2011; 17: 3029-3038 [PMID: 21248297 DOI: 10.1158/1078-0432.CCR-10-2532]
28. Hong L, Han Y, Zhang H, Li M, Gong T, Sun L, Wu K, Zhao Q, Fan D. The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Ann Surg 2010; 251: 1056-1063 [PMID: 20485139 DOI: 10.1097/SLA.0b013e3181dd4ea9]